{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:25:57Z","timestamp":1787199957683,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: The interaction between COVID-19 vaccination and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC) remains incompletely characterized. Methods: Retrospective cohort study of 139 patients with stage IV NSCLC treated with first-line ICI-based therapy, stratified by vaccination status and total doses received (0\u20131 vs. \u22652). Progression-free (PFS) and overall survival (OS) were analyzed by Kaplan\u2013Meier and Cox regression; logistic regression explored factors associated with treatment-related toxicity. Results: Vaccinated patients had longer median PFS (13.0 vs. 11.0 months) and OS (29.0 vs. 24.0 months; both p &lt; 0.001). In multivariable models these associations were attenuated and of borderline significance (OS HR = 0.83, 95% CI 0.69\u20130.99; PFS HR = 0.79, 95% CI 0.62\u20130.99). Outcomes were also more favorable with \u22652 doses (median PFS 14.0 vs. 12.0 months, p = 0.001; median OS 30.0 vs. 24.0 months, p &lt; 0.001), and tumor mutational status was the strongest independent predictor of survival. In an exploratory model, \u22652 doses were associated with higher odds of any-grade toxicity (OR = 2.47, p = 0.037); events were predominantly low grade, with no Grade 4 or 5 toxicity. Conclusions: COVID-19 vaccination was associated with improved PFS and OS in stage IV NSCLC receiving first-line ICI therapy, with a dose-related pattern. The association was attenuated after adjustment for tumor biology and is hypothesis-generating. These findings support the safety and potential clinical relevance of vaccination in this population and underline the need for structured monitoring during immunotherapy. Prospective validation is required.<\/jats:p>","DOI":"10.3390\/medicina62081588","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:12:11Z","timestamp":1787069531000},"page":"1588","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of COVID-19 Vaccination on Patients with Non-Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitor Therapy: Real-World Evidence from Romania"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-5464","authenticated-orcid":false,"given":"Valeriu","family":"Gheorghi\u021b\u0103","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Agrippa Ionescu\u201d Emergency Clinical Hospital, 077015 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia Teodor","family":"Cotan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Pistol","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Maria","family":"Orlov-Slavu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tianu","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Agrippa Ionescu\u201d Emergency Clinical Hospital, 077015 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Teodora","family":"Lazar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miruna","family":"Stanciu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Radoi","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Agrippa Ionescu\u201d Emergency Clinical Hospital, 077015 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mitroi","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Agrippa Ionescu\u201d Emergency Clinical Hospital, 077015 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Ni\u021bipir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100041","DOI":"10.1016\/j.ccmp.2022.100041","article-title":"Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review","volume":"2","author":"Ali","year":"2022","journal-title":"Clin. Complement. Med. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.21037\/tcr-2025-145","article-title":"Impact of smoking on the effectiveness of different non-small-cell lung cancer therapies","volume":"14","author":"Yang","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Riondino, S., Rosenfeld, R., Formica, V., Morelli, C., Parisi, G., Torino, F., Mariotti, S., and Roselli, M. (2024). Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?. Cancers, 16.","DOI":"10.3390\/cancers16071251"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non\u2013Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105123","DOI":"10.1016\/j.esmoop.2025.105123","article-title":"Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: Final, 6-year outcomes from CheckMate 9LA","volume":"10","author":"Carbone","year":"2025","journal-title":"ESMO Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e70274","DOI":"10.1002\/mco2.70274","article-title":"Improvement of the Anticancer Efficacy of PD-1\/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies","volume":"6","author":"Gao","year":"2025","journal-title":"MedComm"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Duroseau, B., Kipshidze, N., and Limaye, R.J. (2023). The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1087138"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1016\/j.vaccine.2023.06.005","article-title":"Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021\u2013January 2022","volume":"41","author":"Boere","year":"2023","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2607893","DOI":"10.1080\/21645515.2025.2607893","article-title":"Vaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research","volume":"22","author":"Sundaram","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I interferon response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.7150\/jca.108163","article-title":"Strategies to Overcome PD-1\/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades","volume":"16","author":"Liu","year":"2025","journal-title":"J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xi, H., Li, M., Shen, J., Lin, Y., Wang, B., Yu, Q., Wang, H., and Zhao, Y. (2026). COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors therapy in cancer patients: A meta-analysis of real-world studies. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1807267"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Boyd","year":"2021","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"ref_21","unstructured":"European Centre for Disease Prevention and Control (2023). Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU\/EEA, ECDC. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41392-025-02521-3","article-title":"When vaccines reset tumors: SARS-CoV-2 mRNA shots create a transient checkpoint-sensitive state","volume":"10","author":"Chi","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fabbri, A., Ruggeri, E.M., Virtuoso, A., Giannarelli, D., Raso, A., Chegai, F., Remotti, D., Signorelli, C., and Nelli, F. (2025). Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study. Cancers, 17.","DOI":"10.3390\/cancers17121948"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fan, Y., Xie, W., Huang, H., Wang, Y., Li, G., Geng, Y., Hao, Y., and Zhang, Z. (2021). Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.633032"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107510","DOI":"10.1016\/j.lungcan.2024.107510","article-title":"Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11\/KEAP1 comutations across PD-L1 levels","volume":"190","author":"Sun","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108058","DOI":"10.1016\/j.lungcan.2024.108058","article-title":"STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status","volume":"199","author":"Favorito","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2026.05.002","article-title":"Overall survival according to COVID-19 mRNA vaccination co-exposure in patients treated with PD-(L)1 inhibitors: A French real-world cohort study","volume":"37","author":"Jourdain","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_31","unstructured":"(2026, June 03). ClinicalTrials.gov\u2014NCT05533697: mRNA-4359 in Combination with Pembrolizumab in Advanced Solid Tumors Including NSCLC, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05533697."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dumas, E., Gougis, P., Gasparollo, L., Spano, J.-P., and Stensrud, M.J. (2026). Time-related biases in observational studies: An illustration with COVID-19 vaccination during immune checkpoint inhibitor therapy. medRxiv.","DOI":"10.1101\/2025.11.03.25339367"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nelli, F., Signorelli, C., Fabbri, A., Giannarelli, D., Virtuoso, A., Giron Berrios, J.R., Marrucci, E., Fiore, C., Schirripa, M., and Chilelli, M.G. (2023). Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study. Cancers, 15.","DOI":"10.3390\/cancers15143625"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e198069","DOI":"10.1172\/jci.insight.198069","article-title":"Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy","volume":"10","author":"Awakoaiye","year":"2025","journal-title":"JCI Insight"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2250022","DOI":"10.1002\/eji.202250022","article-title":"Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity","volume":"53","author":"Provine","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_36","unstructured":"(2026, June 03). Analiza Epidemiologica Factori De Risc Deces Cu COVID-19, Available online: https:\/\/insp.gov.ro\/download\/analiza-epidemiologica-factori-de-risc-deces-cu-covid-19\/."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1588\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:06Z","timestamp":1787199306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081588"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081588","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}